ImageneBio (IKNA) Live Share Price, Invest From India

ImageneBio Stock Performance

as on July 26, 2025 at 6:59 am IST

$1.43
Day's Price Range
$1.43
$1.43
52 Week's Low
52 Week's High
$1.36
52-Week Price Range
$1.48
$1.43
4.90%
Downside
3.47%
Upside

ImageneBio share price movements today

Previous Close: $1.37
Open: $1.43
Volume: 101.0
Day's Low - High: $1.43 - $1.43
52 Week Low - High: $1.36 - $1.48

ImageneBio Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

ImageneBio Stock Fundamentals & Key Indicators

Check ImageneBio market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

0.00

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

0.00%

ImageneBio stock Key Stats

Compare market cap, revenue, PE, and other key metrics of ImageneBio with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
ImageneBio	Buy	$-	NA	NA	0.00%	0.00%

Analyst Recommendation on ImageneBio Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for ImageneBio. Average target price of $23

ImageneBio Share Price Target

Get share price movements and forecasts by analysts on ImageneBio.

What analysts predicted

93.78%UPSIDE

Target Price

$23

Current Price

$1.43

Analyzed by

11 Analysts

Target

$23.00

ImageneBio target price $23, a slight upside of 93.78% compared to current price of $1.43. According to 11 analysts rating.

ImageneBio Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	5	2	1	0	-	-	-	-	-	-
Gross Profit	5	1	0	0	0	0	0	0	0	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-14	-17	-17	-19	-16	-13	-10	-9	-8	-2
Net Profit Margin	-267.63%	-854.04%	-1463.54%	-2957.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

ImageneBio Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	0	13	9	30	15	9	-
Gross Profit	-37	-11	-35	-16	13	8	0
Operating Income	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-
Net Income	-40	-16	-44	-34	-68	-68	-49
Net Profit Margin	-4127.78%	-122.28%	-481.36%	-110.10%	-440.29%	-744.17%	0.00%

Global Institutional Holdings in ImageneBio

Check out the Institutions with significant holdings in ImageneBio.

Funds	Holdings
State Street Corp	0.22%
Blue Owl Capital Holdings LP	9.77%
Bvf Inc	9.56%
Sofinnova Ventures	0.91%
Geode Capital Management, LLC	0.76%

See all

Insights on ImageneBio

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 7 quarters, -19.48M → -2.76M (in $), with an average increase of 50.3% per quarter
POSITIVE IMPACT
Price Rise
In the last 7 days, IKNA stock has moved up by 12.6%
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 79.3% return, outperforming this stock by 95.2%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 66.7% return, outperforming this stock by 138.4%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 6 quarters, 6.40M → 659.0K (in $), with an average decrease of 33.0% per quarter

About ImageneBio

Ikena Oncology, Inc. is a clinical-stage, targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.

Organisation

ImageneBio

FAQs

What is ImageneBio share price today?

ImageneBio share price today is $1.43 as on July 26, 2025 at 1:29 am IST at the close of the market. ImageneBio share today touched a day high of $1.43 and a low of $1.43.

What is the 52 week high and 52 week low for ImageneBio share?

ImageneBio share touched a 52 week high of $1.48 on July 25, 2025 and a 52 week low of $1.36 on July 25, 2025. ImageneBio stock price today i.e. July 26, 2025 at 1:29 am IST is closed at $1.43,which is 3.35% down from its 52 week high and 5.15% up from its 52 week low.

How to invest in ImageneBio Stock (IKNA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for ImageneBio on INDmoney app. Click on Buy button.

What is the minimum amount required to buy ImageneBio Stock (IKNA) from India?

Indian investors can start investing in ImageneBio (IKNA) shares with as little as ₹93.92749786376953 or $1 (as of November 10, 2026 at 6:12 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹939.27 in ImageneBio stock (as per the Rupee-Dollar exchange rate as on November 10, 2026 at 6:12 am IST). Based on ImageneBio share’s latest price of $1.43 as on July 26, 2025 at 1:29 am IST, you will get 6.9930 shares of ImageneBio. Learn more about fractional shares .